Back to Search Start Over

Patient engagement impacts glycemic management with vildagliptin and vildagliptin/metformin (single pill) regimens in type 2 diabetes mellitus (the GLORIOUS study).

Patient engagement impacts glycemic management with vildagliptin and vildagliptin/metformin (single pill) regimens in type 2 diabetes mellitus (the GLORIOUS study).

Authors :
Hermans M
Van Gaal L
Rézette I
Daci E
MacDonald K
Denhaerynck K
Vancayzeele S
De Meester L
Clemens A
Yee B
Abraham I
Source :
Primary care diabetes [Prim Care Diabetes] 2016 Dec; Vol. 10 (6), pp. 425-433. Date of Electronic Publication: 2016 Jul 04.
Publication Year :
2016

Abstract

Aims: To evaluate the real-world effectiveness of vildagliptin and vildagliptin/metformin, combined with patient engagement, on glycemic outcomes. Patient engagement included both clinicians' engaging patients through education and counseling; and patients' self-engagement through disease awareness, lifestyle changes, and medication adherence.<br />Methods: Prospective, observational, open-label, multi-center, pharmacoepidemiologic study of type 2 diabetes mellitus (T2DM) patients treated de novo with vildagliptin or vildagliptin/metformin. Data were collected at baseline (treatment initiation), 105±15d, and ≥145d.<br />Results: The evaluable sample included 896 mainly male (58%), overweight (mean±SD BMI=30.3±5.4kg/m <superscript>2</superscript> ), in later middle age (mean±SD age=64±11years) patients. Over the three visits, mean(±SD) HbA1c levels declined from 8.1%(±1.0) to 7.3%(±1.0) to 7.2%(±0.9); HbA1c control rates rose from 7% to 36% to 43%. Mean±SD FPG levels decreased from 170(±49) to 141(±41) to 139(±42)mg/dL; control rates increased from 12% to 39% to 43% (all p<0.0001). Weight decreased nominally by 2kg (p=0.0290) and BMI by 0.8kg/m <superscript>2</superscript> (p<0.0001). Modeling showed patient engagement activities by clinicians and by patients to be major determinants of glycemic outcomes. No unknown safety signals were detected.<br />Conclusions: Vildagliptin and vildagliptin/metformin are effective and safe oral agents in the management of T2DM, especially if part of a treatment program with active patient engagement by clinicians and empowered patients.<br /> (Copyright © 2016 Primary Care Diabetes Europe. Published by Elsevier Ltd. All rights reserved.)

Details

Language :
English
ISSN :
1878-0210
Volume :
10
Issue :
6
Database :
MEDLINE
Journal :
Primary care diabetes
Publication Type :
Academic Journal
Accession number :
27388795
Full Text :
https://doi.org/10.1016/j.pcd.2016.05.008